Diagnostic analysis of toxic damage due to a dose of zoledronic acid
DOI:
https://doi.org/10.18413/rrpharmacology.10.433Аннотация
Introduction: Comprehensive analysis is necessary to analyze the widespread use of bisphosphonate drugs in the treatment and prevention of various diseases of connective tissue structures. The relevance of the study depends on the impact they have on the patient’s somatic condition, given the number of early and late complications diagnosed by domestic and foreign clinicians.
Materials and methods: The methodology used was developed on Stavropol Regional Clinical Hospital from 2010 to 2022. A randomized and observational study of the state of connective tissue structures was conducted in 186 patients who had a history of taking zoledronic acid and developed bisphosphonate osteonecrosis of the jawbone. At the diagnostic and treatment stages, patients were tested using laboratory methods to monitor amino acids in biological fluids (blood), as well as bone blocks extracted intraoperatively using highly effective gas-liquid chromatography on AAA 500.
Results and discussion: Aminograms obtained in the pre-operative period indicate toxic effects of zoledronic acid on neuro, endocrine, and other human systems. The initiation and progression of aseptic inflammatory processes in tissue structures is correlated with the deteriorating general ocular status of patients when amino acids, such as alanine, serine, taurine, phenylalanine, tyrosine, proline, histidine, glycine, and valine, against a background of 90.4±2.1 mmol/L ammonia are reduced critically.
Conclusion: Zoledronic acid initiates an aseptic chronic inflammatory process in the jaw bones, accompanied by toxic acidosis, which worsens osteoporotic symptoms.
Графическая аннотация
Ключевые слова:
amino acids, highly effective gas-liquid chromatography, jawbone resectionБиблиографические ссылки
Amin H, Andersen SWM, Jensen SS, Kofod T (2024) Surgical and conservative treatment outcomes of medication-related osteonecrosis of the jaw located at tori: a retrospective study. Oral and Maxillofacial Surgery. https://doi.org/10.1007/s10006-024-01214-5. Epub ahead of print [PubMed]
Anastasilakis AD, Pepe J, Napoli N, Palermo A, Magopoulos C, Khan AA, Zillikens MC, Body JJ (2022) Osteonecrosis of the jaw and antiresorptive agents in benign and malignant diseases: A critical review organized by the ECTS. The Journal of Clinical Endocrinology and Metabolism 107(5): 1441–1460. https://doi.org/10.1210/clinem/dgab888 [PubMed] [PMC]
Dhillon S (2016) Zoledronic acid (Reclast®, Aclasta®): A review in osteoporosis. Drugs 76(17): 1683–1697. https://doi.org/10.1007/s40265-016-0662-4 [PubMed]
Everts-Graber J, Lehmann D, Burkard JP, Schaller B, Gahl B, Häuselmann H, Studer U, Ziswiler HR, Reichenbach S, Lehmann T (2022) Risk of osteonecrosis of the jaw under denosumab compared to bisphosphonates in patients with osteoporosis. Journal of Bone and Mineral Research 37(2): 340–348. https://doi.org/10.1002/jbmr.4472 [PubMed]
Fernandes TL, Viezzer Fernandes B, Franco GCN (2024) Treatment of medication-related osteonecrosis of the jaws without segmental resections: A case series. The American Journal of Case Reports 25: e942980. https://doi.org/10.12659/AJCR.942980 [PubMed] [PMC]
Ferreira LH Jr, Mendonça KD Jr, Chaves de Souza J, Soares Dos Reis DC, do Carmo Faleiros Veloso Guedes C, de Souza Castro Filice L, Bruzadelli Macedo S, Soares Rocha F (2021) Bisphosphonate-associated osteonecrosis of the jaw. Minerva Dental and Oral Science 70(1): 49–57. https://doi.org/10.23736/S2724-6329.20.04306-X [PubMed]
Gandylyan KS, Sletova VA, Gabbasova IV, Idrisova AM, Elsieva IS, Sletov AA (2023) Analysis of mineral elements in connective tissues in patients with bisphosphonate osteonecrosis. Russian Dental Journal [Rossiiskii Stomatologicheskii Zhurnal] 27(4): 311–321. https://doi.org/10.17816/dent472106 [in Russian]
Golovanova IA,Tomashevsky OA(2019) Kinetics and thermodynamics of the formation of calcium ion compounds with amino acids, their structure and stability. Journal of Physical Chemistry [Zhurnal Fizicheskoi Khimii] 93(1): 11–22. https://doi.org/10.1134/S0044453719010084 [in Russian]
Kim HY (2021) Review and update of the risk factors and prevention of antiresorptive-related osteonecrosis of the jaw. Endocrinology and Metabolosm 36(5): 917–927. https://doi.org/10.3803/EnM.2021.1170 [PubMed] [PMC]
Loktionova MV, Gandylian KS. Kravan SN (2022) Monitoring of amino acid balance indicators in patients with bisphosphonate osteonecrosis of jawbone. New in the theory and practice of dentistry: Proceedings of the XXI Forum of Scientific and Practical Conference of Dentists of the South of Russia ”Actual Questions of Clinical Dentistry”, dedicated to the 75th anniversary of the birth of Professor V.I. Grechishnikov, Stavropol, April 21-22, pp. 159–161. [in Russian]
Martins LHI, Ferreira DC, Silva MT, Motta RHL, Franquez RT, Bergamaschi CC (2023) Frequency of osteonecrosis in bisphosphonate users submitted to dental procedures: A systematic review. Oral Diseases 29(1): 75–99. https://doi.org/10.1111/odi.14003[PubMed]
Polyakov KA, Medvedev YuA, Ivanyushko TP, Sedova MV (2016) Medicine-associated osteonecrosis of jaw: A comparative analysis of oral microflora in health, in case of osteomyelitis and osteonecrosis of jaws. Modern Science. 9: 83–87.
Rodionova SS, Kolondaev AF, Torgashin AN, Solomyannik IA (2022) Zoledronic acid for osteoporosis and associated low energy fractures. Medical Council [Meditsinskii Sovet] 16(21): 163–173. https://doi.org/10.21518/2079-701X-2022-16-21-163-173 [in Russian]
Ruggiero SL, Dodson TB, Aghaloo T, Carlson ER, Ward BB, Kademani D (2022) American Association of Oral and Maxillofacial Surgeons’ position paper on medication-related osteonecrosis of the jaws-2022 update. Journal of Oral and Maxillofacial Surgery 80(5): 920–943. https://doi.org/10.1016/j.joms.2022.02.008 [PubMed]
Shcheblykin DV, Bolgov AA, Pokrovskii MV, Stepenko JV, Tsuverkalova JM, Shcheblykina OV, Golubinskaya PA, Korokina LV (2022) Endothelial dysfunction: developmental mechanisms and therapeutic strategies.Research Results in Pharmacology 8(4): 115–139. https://doi.org/10.3897/rrpharmacology.8.80376
Sogacheva VV, Syomkin VA (2022) Bisphosphonate-related osteonecrosis of the jaws. Dentistry [Stomatologiya] 101(6): 85–90. https://doi.org/10.17116/stomat202210106185[PubMed] [in Russian]
Загрузки
Опубликован
Как цитировать
Выпуск
Раздел
Лицензия
Copyright (c) 2024 Irina V. Gabbasova, Valeria A. Sletova, Alina D. Oksentyuk, Irina L. Abisalova, Kristina S. Gandylian, Zhou Ling, Roman R. Saltovets, Zhanna I. Glushanyan, Hasan A. Ordashev, Arsen K. Shakhbanov, Dmitry V. Mikhalchenko, Said A. Shakhbanov, Biyke R. Isaeva, Asiyat A. Idrisova, Oleg I. Admakin, Marina V. Loktionova, Oksana V. Vorobyeva, Tang Hui, Aleksandr A. Sletov
Это произведение доступно по лицензии Creative Commons «Attribution» («Атрибуция») 4.0 Всемирная.